AbbVie’s venetoclax fails Phase III myeloma trial

AbbVie reported negative results from a Phase III CANOVA trial investigating venetoclax in patients with relapsed or refractory multiple myeloma.

The trial evaluated the safety and efficacy of venetoclax in combination with dexamethasone (VenDex) compared with pomalidomide plus dexamethasone (PomDex). According to the announcement, the VenDex combo treatment did not significantly improve progression-free survival (PFS), which was the primary endpoint.